Empagliflozin (SGLT2 inhibitors) and Diabetic ketoacidosis: is the FAERS signal real?
Empagliflozin (SGLT2 inhibitors) ↔ Diabetic ketoacidosis
SGLT2 inhibitors including empagliflozin cause a distinctive ketoacidosis that can occur at near-normal blood glucose levels — so-called euglycaemic diabetic ketoacidosis — which makes it easy to miss because clinicians are taught to screen for DKA using glucose alone. The FDA warned about this in 2015 and required labeling changes, and the mechanism is now understood: glucosuria masks the usual hyperglycaemic signal while the drugs shift substrate use toward ketogenesis, especially during fasting, illness, surgery, or insulin reduction. Risk is higher with off-label use for weight loss, in type 1 diabetes, and around procedures. It is a genuine, mechanistically coherent class effect with a clear regulatory history, and the large PRR here reflects both the true risk and the intensive reporting prompted by the FDA warning.
Regulatory basis: FDA safety communications on SGLT2-inhibitor ketoacidosis (2015), with subsequent labeling changes. SGLT2-inhibitor DKA literature (euglycaemic DKA).
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Occurs during exposure, often triggered by fasting, illness, or insulin changes |
| Strength | met | PRR 60, one of the largest class signals on the page |
| Consistency | met | Reported across the whole SGLT2 class and multiple countries |
| Specificity | met | The euglycaemic pattern is characteristic of SGLT2 inhibitors |
| Biological gradient | partial | Higher with off-label weight-loss use and type 1 diabetes than standard type 2 dosing |
| Plausibility | met | Glucosuria plus a shift toward ketogenesis — a defined metabolic mechanism |
| Coherence | met | Coheres with the shared class pharmacology and the FDA warning |
| Experiment | partial | Labeled precautions and peri-procedural drug holds reduce risk; no dedicated randomized trial |
| Analogy | met | Directly analogous across all SGLT2 inhibitors |
This page's own qualitative read, not an automated/citation-gated assessment.
✓ Trial evidence found — empagliflozin vs DPP-4 inhibitors, post-authorization safety study (NCT03764631), N=1,502
| Term (as recorded) | Empagliflozin (n=751) | DPP-4 inhibitors (n=751) |
|---|---|---|
| Diabetic ketoacidosis (serious) | 1 | 1 |
This dedicated post-authorization study tracked ketoacidosis as a prespecified event — confirming it is a recognized SGLT2 risk — but recorded only one event per arm over 12 months, far too few to quantify the difference. The signal was established from spontaneous reporting and the FDA’s 2015 safety review, not from a trial this size. View on ClinicalTrials.gov →